Matinas BioPharma
MTNB
50 hedge funds and large institutions have $12.6M invested in Matinas BioPharma in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 10 reducing their positions, and 9 closing their positions.
0.01% less ownership
Funds ownership: 0.25% → 0.25% (-0.01%)
7% less capital invested
Capital invested by funds: $13.6M → $12.6M (-$1.01M)
12% less funds holding
Funds holding: 57 → 50 (-7)
30% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 10
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$77.6K |
| 2 |
MWM
Modera Wealth Management
Westwood,
New Jersey
|
+$47.8K |
| 3 |
SS
Simplicity Solutions
Minneapolis,
Minnesota
|
+$30.3K |
| 4 |
Renaissance Technologies
New York
|
+$25.7K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$8.52K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$125K |
| 2 |
Jane Street
New York
|
-$74.4K |
| 3 |
VF
Virtu Financial
New York
|
-$72K |
| 4 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$67.2K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$50.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of America
Charlotte,
North Carolina
| $3 | -$480 | -19 | Closed |
|
|
VF
52
Virtu Financial
New York
| – | -$72K | -2,882 | Closed |
|
|
HF
53
HRT Financial
New York
| – | -$27K | -1,091 | Closed |
|
54
Citadel Advisors
Miami,
Florida
| – | -$26.1K | -1,042 | Closed |
|
|
ECM
55
ExodusPoint Capital Management
New York
| – | -$23K | -920 | Closed |
|
56
Goldman Sachs
New York
| – | -$17.6K | -704 | Closed |
|
57
Victory Capital Management
San Antonio,
Texas
| – | -$11.8K | -473 | Closed |
|
58
UBS Group
Zurich,
Switzerland
| – | -$5.93K | -237 | Closed |
|
59
Citigroup
New York
| – | -$90 | -4 | Closed |
|
MTNB Hedge Fund Activity: Q1 2023 in Review
50 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2023, worth a combined $12.6M — down 7.4% from $13.6M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of MTNB and 2 opened new positions — a net loss of 7 holders — while 10 trimmed existing stakes and 7 added.
The largest buyer was Vanguard Group, adding an estimated $77.6K. The largest seller was BlackRock, cutting an estimated $125K.
- 50 institutional investors held Matinas BioPharma (MTNB) as of Q1 2023, down from 57 in Q4 2022.
- Funds reported $12.6M of Matinas BioPharma stock for Q1 2023, down 7.4% quarter-over-quarter.
- 2 funds opened new Matinas BioPharma positions in Q1 2023 and 9 closed out, a net change of -7 holders.
- The largest Matinas BioPharma buyer in Q1 2023 was Vanguard Group, an estimated $77.6K added.
- The largest Matinas BioPharma seller in Q1 2023 was BlackRock, an estimated $125K sold.
Based on aggregated 13F filings for Q1 2023.